High rate of hypoglycemia in diabetic pregnant women on use of glyburide
© De Bacco et al. 2015
Published: 11 November 2015
The prevalence of gestational diabetes (GD) in Brazil can exceed 18% when applied the current WHO diagnostic criteria. The importance of the GD treatment in reducing severe outcomes of perinatal maternal morbidity and has been shown in randomized clinical trials. Therapeutic options for the GD have included oral antidiabetic agents glibenclamide (GB) and metformin (MF) showed Results of safety and efficacy similar to insulin.
To analyze the effects of the use of GB and MF in the treatment of GD in pregnant women at a specialized clinic in HCPA in a randomized open-label study.
Materials and methods
Eighty-one women diagnosed with GD and drug treatment indication were randomized. The initial dose of GB was 2.5 mg/day with an increase of 2.5 mg next week and new increments of 5 mg/week to achieve glycemic targets or maximum dose (20mg/day); MF is an initial dose of 500mg to 500mg increments every 3 days to obtain the target or maximum dose of 2.5 g/day.
Thirty-six patients were randomized to the MT group and 45 for the GB group. The slurry treatment rate were 22.9% and 54.5%, respectively MP and GB group (p=0.006). Reasons for discontinuation of medications is hypoglycemia: 2.9% and 38.6% (p <0.001), respectively MF and GB group; not glycemic compensation: 2.9% and 13.6% (p=0.095), respectively MF and G groups); and gastric intolerance: 17.1% and 2.3% (p=0.021) respectively MF group and GB.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.